Arbutus Biopharma
Arbutus Biopharma
ABUS
NASDAQ
3.35
USD
1.82%
About
Arbutus Biopharma Corporation is a clinical-stage biopharmaceutical company. The Company is leveraging its virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can potentially be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV) infection.
Its HBV product pipeline includes Imdusiran and AB-101. Imdusiran is its proprietary, conjugated GalNAc, subcutaneously delivered RNAi therapeutic product candidate. AB-101 is an oral PD-L1 inhibitor that has the potential to reawaken patients’ HBV-specific immune response by inhibiting PD-L1. Its pipeline includes two product candidates that target various steps in the HBV viral lifecycle and consists of various programs: RNAi therapeutic (imdusiran, AB-729) and Oral PD-L1 Inhibitor (AB-101).
RNAi therapeutics utilize a natural pathway within cells to silence genes by eliminating the disease-causing proteins that they code for..
Financials Amount (in millions)
Income statement
Balance sheet
Cash flow
Ratios
| Price and Volume | |
|---|---|
| Volume | |
| Ten Day Average Volume | 902.5K |
| Three Month Average Volume | 20.6M |
| High Low | |
| Fifty-Two Week High | 3.98 USD |
| Fifty-Two Week Low | 1.69 USD |
| Fifty-Two Week High Date | 26 Jul 2024 |
| Fifty-Two Week Low Date | 24 Oct 2023 |
| Price and Volume | |
| Current Price | 3.87 USD |
| Beta | 2 |
| Relative Price Change | |
| Four Week Relative Price Change | -1.92% |
| Thirteen Week Relative Price Change | 7.62% |
| Twenty-Six Week Relative Price Change | 26.15% |
| Fifty-Two Week Relative Price Change | 52.14% |
| Year-to-Date Relative Price Change | 30.72% |
| Price Change | |
| One Day Price Change | 1.04% |
| Thirteen Week Price Change | 15.18% |
| Twenty-Six Week Price Change | 38.71% |
| Five Day Price Change | -0.51% |
| Fifty-Two Week Price Change | 90.64% |
| Year-to-Date Price Change | 54.80% |
| Month-to-Date Price Change | 2.65% |
| Per Share Data | |
|---|---|
| Book Value | |
| Book Value Per Share (Last Fiscal Year) | 0.62412 USD |
| Book Value Per Share (Most Recent Quarter) | 0.6488 USD |
| Tangible Book Value Per Share (Last Fiscal Year) | 0.62412 USD |
| Tangible Book Value Per Share (Most Recent Quarter) | 0.6488 USD |
| EBITD | |
| EBITD Per Share (Trailing Twelve Months) | -0.46765 USD |
| Revenue | |
| Revenue Per Share (Last Fiscal Year) | 0.10931 USD |
| Revenue Per Share (Trailing Twelve Months) | 0.05751 USD |
| Dividend | |
| Dividend Per Share (Last Fiscal Year) | -99999.99 USD |
| Dividend Per Share (Trailing Twelve Months) | 0 USD |
| Dividend Per Share (5 Year) | -99999.99 USD |
| Earnings Per Share | |
| Excluding Extraordinary Items (Last Fiscal Year) | -0.43895 USD |
| Excluding Extraordinary Items (Trailing Twelve Months) | -0.44161 USD |
| Normalized (Last Fiscal Year) | -0.43895 USD |
| Basic Excluding Extraordinary Items (Last Fiscal Year) | -0.43895 USD |
| Basic Excluding Extraordinary Items (Trailing Twelve Months) | -0.44161 USD |
| Including Extraordinary Items (Last Fiscal Year) | -0.43895 USD |
| Including Extraordinary Items (Trailing Twelve Months) | -0.44161 USD |
| Cash | |
| Cash Per Share (Last Fiscal Year) | 0.74177 USD |
| Cash Per Share (Most Recent Quarter) | 0.75229 USD |
| Cash Flow Per Share (Last Fiscal Year) | -0.43049 USD |
| Cash Flow Per Share (Trailing Twelve Months) | -0.43242 USD |
| Free Cash Flow Per Share (Trailing Twelve Months) | -0.4173 USD |
| Margins | |
|---|---|
| Cash Flow Revenue | |
| Cash Flow Revenue (5 Year) | -388 |
| Cash Flow Revenue (Trailing Twelve Months) | -726 |
| Pretax Margin | |
| Pretax Margin (Trailing Twelve Months) | -766.20% |
| Pretax Margin (Last Fiscal Year) | -401.57% |
| Pretax Margin (5 Year) | -547.94% |
| Gross Margin | |
| Gross Margin (Last Fiscal Year) | -99,999.99% |
| Gross Margin (Trailing Twelve Months) | -99,999.99% |
| Gross Margin (5 Year) | -99,999.99% |
| Operating Margin | |
| Operating Margin (Last Fiscal Year) | -430.53% |
| Operating Margin (Trailing Twelve Months) | -827.46% |
| Operating Margin (5 Year) | -516.56% |
| Net Profit Margin | |
| Net Profit Margin (Last Fiscal Year) | -401.57% |
| Net Profit Margin (Trailing Twelve Months) | -766.20% |
| Net Profit Margin (5 Year) | -537.81% |
| Growth | |
|---|---|
| Book Value | |
| Book Value Per Share (5 Year) | -29.59% |
| Tangible Book Value (5 Year) | -4.57% |
| Free Operating Cash Flow | |
| Free Operating Cash Flow (5 Year) | -99,999.99% |
| Revenue | |
| Revenue Change MRQ vs 1 Year Ago | -62.89% |
| Revenue Growth (3 Year) | 25.00% |
| Revenue Change (Trailing Twelve Months) | -57.25% |
| Revenue Per Share Growth | 0.33% |
| Revenue Growth (5 Year) | 37.93% |
| Capital Spending Debt | |
| Capital Spending (5 Year) | -2.40% |
| Total Debt (5 Year) | -99,999.99% |
| Dividends | |
| Dividend Growth (3 Year) | -99,999.99% |
| Earnings Per Share | |
| EPS Change MRQ vs 1 Year Ago | -2.26% |
| EPS Change (Trailing Twelve Months) | 4.27% |
| EPS Growth (3 Year) | -99,999.99% |
| EPS Growth (5 Year) | -99,999.99% |
| EBITDA | |
| EBITDA (5 Year) | -99,999.99% |
| EBITDA (5 Year Interim) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin Growth (5 Year) | -99,999.99% |
| Valuation | |
|---|---|
| Total Price to Book | |
| Price to Tangible Book (Last Fiscal Year) | 7 |
| Price to Tangible Book (Most Recent Quarter) | 6 |
| Price to Free Cash Flow | |
| Price to Free Cash Per Share (Last Fiscal Year) | -100,000 |
| Price to Free Cash Per Share (Trailing Twelve Months) | -100,000 |
| Net Debt | |
| Net Debt (Most Recent Quarter) | -141,986,000 |
| Net Debt (Last Fiscal Year) | -126,003,000 |
| Price to Sales | |
| Price to Sales (Last Fiscal Year) | 40 |
| Price to Sales (Trailing Twelve Months) | 73 |
| Price to Earnings | |
| PE Excluding Extraordinary Items (Last Fiscal Year) | -100,000 |
| PE Normalized (Last Fiscal Year) | -100,000 |
| PE Basic Excluding Extraordinary Items (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items High (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items Low (Trailing Twelve Months) | -100,000 |
| PE Including Extraordinary Items (Trailing Twelve Months) | -100,000 |
| Dividends | |
| Dividend Yield (5 Year) | -99,999.99% |
| Dividend Yield | -99,999.99% |
| Current Dividend Yield | 0.00% |
| Price to Book | |
| Price to Book (Last Fiscal Year) | 6 |
| Price to Book (Most Recent Quarter) | 6 |
| Financial Strength | |
|---|---|
| Debt to Equity | |
| Long Term Debt to Equity (Last Fiscal Year) | 0 |
| Long Term Debt to Equity (Most Recent Quarter) | 0 |
| Payout Ratio | |
| Payout Ratio (Last Fiscal Year) | -99,999.99% |
| Payout Ratio (Trailing Twelve Months) | -99,999.99% |
| Quick Ratio | |
| Quick Ratio (Last Fiscal Year) | -100,000 |
| Quick Ratio (Most Recent Quarter) | -100,000 |
| Enterprise Value | |
| Current Enterprise Value to Free Cash Flow (Last Fiscal Year) | -100,000 |
| Current Enterprise Value to Free Cash Flow (Trailing Twelve Months) | -100,000 |
| Current Ratio | |
| Current Ratio (Last Fiscal Year) | 6 |
| Current Ratio (Most Recent Quarter) | 7 |
| Free Cash Flow | |
| Free Cash Flow (Last Fiscal Year) | -86,944,000 |
| Free Cash Flow (Trailing Twelve Months) | -73,003,000 |
| Net Interest Coverage | |
| Net Interest Coverage (Last Fiscal Year) | -100,000 |
| Net Interest Coverage (Trailing Twelve Months) | -100,000 |
| Total Debt to Equity | |
| Total Debt to Equity (Last Fiscal Year) | 0 |
| Total Debt to Equity (Most Recent Quarter) | 0 |
| Management Effectiveness | |
|---|---|
| Return on Assets | |
| Return on Assets (Last Fiscal Year) | -42.88% |
| Return on Assets (Trailing Twelve Months) | -45.77% |
| Return on Assets (5 Year) | -52.62% |
| Return on Equity | |
| Return on Equity (Last Fiscal Year) | -59.99% |
| Return on Equity (Trailing Twelve Months) | -59.96% |
| Return on Equity (5 Year) | -165.78% |
| Return on Investment | |
| Return on Investment (Last Fiscal Year) | -51.22% |
| Return on Investment (Trailing Twelve Months) | -53.21% |
| Return on Investment (5 Year) | -58.11% |